
https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents


INTRODUCTION

Recent guidance from the World Health Organization (WHO) recognizes the adverse health effects of criminalizing drug use, especially its role in harming population health. The WHO’s recent guidance emphasizes the necessity of decriminalizing drug use and creating health-friendly policies to address drug and overdose harm. 

The Canadian Medical Association (CMA) has long advocated for evidence-based drug policies that promote health and well-being. The CMA’s Policy 14443, “CSAM–SMCA in Support of the Decriminalization of Drug Use and Possession for Personal Use,” outlines the Association’s position on the need for equitable, health-focused drug policies.

This policy provides guidance for evidence-based drug policies, emphasizing the importance of decriminalizing drug use and creating health-friendly approaches to address drug and overdose harm. The CMA supports the decriminalization of drug use and encourages the development of evidence-based policies that prioritize health and well-being.

Support life-saving supervised consumption and overdose prevention sites:

CMA Policybase - Canadian Medical Association
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE Policy endorsement
DATE 2018-08-30
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Canada's lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Policy endorsement</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2017-05-26</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**